Data Sharing Statement

Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. DOI: 10.1056/NEJMoa2105290.

Question	Authors' Response
Will the data collected for your study be made available	Yes
to others?	
Would you like to offer context for your decision?	-
Which data?	_
Additional information about data	_
How or where can the data be obtained?	Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
When will data availability begin?	Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
When will data availability end?	_
Will any supporting documents be available?	_
Which supporting documents?	_
Additional information about supporting documents	_
How or where can supporting documents be obtained?	_
When will supporting documents availability begin?	_
When will supporting documents availability end?	_
To whom will data be available?	AstraZeneca Group of Companies allows researchers to submit a request to access anonymized patient level clinical data, aggregate clinical or genomics data (when available) and/or anonymized clinical study reports through Vivli web-based data request platform.
For what type of analysis or purpose?	Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
By what mechanism?	Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Any other restrictions?	_
Additional information	